Skip to main content
SpringerLink
Log in
Book cover

Patient Surveillance After Cancer Treatment pp 235–241Cite as

Soft Tissue Sarcoma Surveillance Counterpoint: Canada

  • Chapter
  • First Online:

  • 137 Accesses

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Soft tissue sarcomas are malignant tumors derived from mesenchymal tissue outside the skeleton. In addition to being comparatively rare (<1 % of all cancers), many histological subtypes are recognized, and soft tissue sarcoma can arise in any anatomical location [1]. This heterogenity presents a challenge to the development of management and follow-up guidelines. This counterpoint will focus on adult soft tissue sarcomas, divided into extremity and non-extremity groupings. Also included are separate sections on gastrointestinal stromal tumors (GIST) focusing on their unique biology, treatment, and follow-up. The short- and long-term morbidities of treatment for cancers occurring in children are very different from those seen in adults and require different follow-up protocols. For this reason, pediatric rhabdomyosarcomas will not be covered in this counterpoint. Although nominally a sarcoma, Kaposi’s sarcoma is a multifocal malignant spindle cell proliferation seen almost exclusively now in the setting of acquired immunodeficiency syndrome (AIDS) associated with human immunodeficiency virus (HIV) infection. These spindle cells express endothelial and macrophage markers and are thought to originate from circulating peripheral blood hematopoietic precursor cells [2]. In Chapter 42, Wadhwa and Johnson state that the highest rates of connective tissue tumors in the world are seen in South Africa and Uganda. However, these figures are certainly skewed by the inclusion of AIDS-related Kaposi sarcomas, whose incidence correlates with the prevalence of HIV infection in a given country. Given that Kaposi sarcomas have nothing in common with classic adult soft tissue sarcomas, they will not be considered further in this counterpoint.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Weiss SW, Goldblum JR. Enzinger and Weiss’s soft tissue tumors. 4th ed. Marc Strauss editor. Mosby, Inc. 2001. p7–8.

    Google Scholar 

  2. Ambinder RF. Chapter 98 HIV associated malignancies, p2649. In: Abeloff JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Clinical oncology. 3rd ed. Churchill, Livin`one: Elsevier; 2004.

    Google Scholar 

  3. Cancer care Ontario: cancer in young adults in Canada, Toronto, Canada 2006. ISBN 0-921325-10-X. Also available at htpp://www.cancercare.on.ca.

  4. Paszat L, O’Sullivan B, Bell R, Bramwell V, Groome P, MacKillop W, et al. Processes and outcomes of care for soft tissue sarcoma of the extremities. Sarcoma. 2002;6:19–26.

    Article  PubMed  Google Scholar 

  5. Enneking W. Modification of the system for functional evaluation in the surgical management of musculoskeletal tumors. In: Enneking W, editor. Limb salvage in musculoskeletal oncology. New York, NY: Churchill, Livingstone; 1987. p. 627–39.

    Google Scholar 

  6. Davis AM, Wright JG, Williams JI, Bombardier C, Griffin A, Bell RS. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res. 1996;5:508–16.

    Article  PubMed  CAS  Google Scholar 

  7. Soft tissue sarcoma. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer, 2002. p. 193–197.

    Google Scholar 

  8. Kattan NW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791–6.

    Article  PubMed  Google Scholar 

  9. Heslin MJ, Smith JK. Imaging of soft tissue sarcomas. Surg Oncol Clin N Am. 1999;8:91–107.

    PubMed  CAS  Google Scholar 

  10. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol. 2006;18:369–73.

    Article  PubMed  Google Scholar 

  11. Toner GC, Hicks RJ. PET for sarcomas other than gastrointestinal stromal tumors. Oncologist. 2008;13 Suppl 2:22–6.

    Article  PubMed  Google Scholar 

  12. Welker J, Henshaw RM, Jelinek J, Shmookler BM, Malawer MM. The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer. 2000;89:2677–86.

    Article  PubMed  CAS  Google Scholar 

  13. Coindre JM, Nguyen BB, Bonichon F, de Mascarel I, Trojani M. Histopathologic grading in spindle cell soft tissue sarcomas. Cancer. 1988;61:2305–9.

    Article  PubMed  CAS  Google Scholar 

  14. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol. 2002;33:459–65.

    Article  Google Scholar 

  15. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196:305–15.

    Article  PubMed  CAS  Google Scholar 

  16. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197–203.

    PubMed  CAS  Google Scholar 

  17. Pisters PW, Harrison LB, Woodruff JM, Gaynor JJ, Brennan MF. A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J Clin Oncol. 1994;12:1150–5.

    PubMed  CAS  Google Scholar 

  18. Mack LA, Crowe PJ, Yang JL, Schachar NS, Morris DG, Kurien EC, et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol. 2004;12:646–53.

    Article  Google Scholar 

  19. O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomized trial. Lancet. 2002;359:2235–41.

    Article  PubMed  Google Scholar 

  20. Davis AM, O’Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2002;20:4471–7.

    Article  Google Scholar 

  21. Davis AM, O’Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. A Canadian Sarcoma Group and NCI Canada Clinical Trials Group Randomized Trial: late radiation therapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75:48–53.

    Article  PubMed  Google Scholar 

  22. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228:355–65.

    Article  PubMed  CAS  Google Scholar 

  23. Pawlik TM, Pisters PWT, Mikula L, Feig BW, Hunt KK, Cormier JN, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13: 508–17.

    Article  PubMed  Google Scholar 

  24. DeMatteo RP, Heinrich MC, El-rifai WM, Demetri G. Clinical Management of gastrointestinal stromal tumors: before and after STI-571. Human Pathol. 2002;33:466–77.

    Article  CAS  Google Scholar 

  25. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7.

    Article  PubMed  CAS  Google Scholar 

  26. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Judson I, for the EORTC soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, and the Australasian Gastrointestinal Trials Group: progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet. 2004;364:1127–34.

    Article  PubMed  CAS  Google Scholar 

  27. Blanke CD, Rankin C, Demetri GD, Ryan CS, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.

    Article  PubMed  CAS  Google Scholar 

  28. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY. ESMO Guidelines Working Group: soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 (Suppl ii):89–93.

    Google Scholar 

  29. Zagars GK, Ballo MT, Pisters PWT, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1224 patients. Cancer. 2003;97:2530–43.

    Article  PubMed  Google Scholar 

  30. Pisters PWT, Leung DHY, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcoma of the extremities. J Clin Oncol. 1996;14:1679–89.

    PubMed  CAS  Google Scholar 

  31. Eilber FC, Rosen G, Nelson SD, Selch M, Dorey F, Eckardt J, Eilber FR. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003;237(2):218–26.

    PubMed  Google Scholar 

  32. Coindre JM, Terrier P, Guillou L, Doussal VL, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2003;91:1914–26.

    Article  Google Scholar 

  33. Stojadinovic A, Leung DHY, Allen P, Lewis JJ, Jaques DP, Brennan MF. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol. 2002;20:4344–52.

    Article  PubMed  Google Scholar 

  34. Bramwell VH, Anderson D, Charette ML, Sarcoma Disease Site Group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003;(3): CD003293.

    Google Scholar 

  35. Gadd MA, Casper ES, Woodruff JM, McCormack PM, Brennan MF. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993;218:705–12.

    Article  PubMed  CAS  Google Scholar 

  36. Potter DA, Glenn J, Kinsella T, Glatstein E, Lack EE, Restrepo C, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol. 1985;3:353–66.

    PubMed  CAS  Google Scholar 

  37. Pastorino U, Buyse M, Frieel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37–49.

    Article  Google Scholar 

  38. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001;234:540–7.

    Article  PubMed  CAS  Google Scholar 

  39. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14–24.

    Article  PubMed  Google Scholar 

  40. Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D, et al. Secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2007;99:300–8.

    Article  PubMed  Google Scholar 

  41. Kingston JE, Hawkins MM, Draper GJ, Marsden HB, Kinnier Wilson LM. Patterns of multiple primary tumours in patients treated for cancer during childhood. Br J Cancer. 1987;56:331–8.

    Article  PubMed  CAS  Google Scholar 

  42. Krumerman MS, Stingle W. Synchronous malignant glandular schwannomas in congenital neurofibromatosis. Cancer. 1978;41: 2444–51.

    Article  PubMed  CAS  Google Scholar 

  43. Agaimy A, Wunsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diag Pathol. 2006;23:120–9.

    Article  Google Scholar 

  44. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003;9:1941–56.

    PubMed  Google Scholar 

  45. Nielsen TO. Microarray analysis of sarcomas. Adv Anat Pathol. 2006;13(4):166–73.

    Article  PubMed  CAS  Google Scholar 

  46. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–90.

    Article  PubMed  CAS  Google Scholar 

  47. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Nat Clin Pract Oncol. 2007; 4:342–3.

    Article  Google Scholar 

  48. White JS, Biberdorf D, DiFrancesco LM, Kurien E, Temple WJ. Use of tissue expanders and pre-operative external beam radiotherapy in the treatment of retroperitoneal sarcoma. Ann Surg Oncol. 2007;14:583–90.

    Article  PubMed  CAS  Google Scholar 

  49. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a ranedomised, double-blind, placebo-controlled trial. Lancet. 2009;373: 1097–104.

    Article  PubMed  CAS  Google Scholar 

  50. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:739–47.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Alberta Health Services—Cancer Care, Tom Baker Cancer Centre, University of Calgary, Surgical Oncologist, 1331 – 29 Street NW, Calgary, AB, Canada, T2N 4N2

    Lloyd A. Mack M.D., F.R.C.S.C., F.A.C.S.

  2. Department of Medicine, Alberta Health Services—Cancer Care, Tom Baker Cancer Centre, University of Calgary, 1331 – 29 Street NW, Calgary, AB, Canada, T2N 4N2

    Vivien H. C. Bramwell Ph.D., M.B.B.S., F.R.C.P.C.

  3. Division of Medical and Radiation Oncology, Alberta Health Services, Calgary Zone, 1331 – 29 Street NW, Calgary, AB, Canada, T2N 4N2

    Vivien H. C. Bramwell Ph.D., M.B.B.S., F.R.C.P.C.

Authors
  1. Lloyd A. Mack M.D., F.R.C.S.C., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivien H. C. Bramwell Ph.D., M.B.B.S., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lloyd A. Mack M.D., F.R.C.S.C., F.A.C.S. .

Editor information

Editors and Affiliations

  1. Department of Surgery, Saint Louis University, Vista Avenue 3635, St. Louis, 63110-0050, Missouri, USA

    Frank E. Johnson

  2. Fac. Medicine, Dept. Surgery II, Kyushu University, Fukuoka, 812-8582, Japan

    Yoshihiko Maehara

  3. BC Cancer Agency, West 10th Avenue 600, Vancouver, V5Z 4E6, British Columbia, Canada

    George P. Browman

  4. School of Medicine, Washington University, S. Euclid Ave. 660, St. Louis, 63110, Missouri, USA

    Julie A. Margenthaler

  5. St Helens Teaching Hospital, University of Liverpool, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom

    Riccardo A. Audisio

  6. Sydney Cancer Centre, Sydney Melanoma Unit, Royal Prince Alfred Hospital, Missenden Road, Camperdown, 2050, New South Wales, Australia

    John F. Thompson

  7. Saint Louis University Medical Center, Saint Louis, 63103, Missouri, USA

    David Y. Johnson

  8. Dana-Farber Cancer Institute, Harvard Medical School, Binney St. 44, Boston, 02115, Massachusetts, USA

    Craig C. Earle

  9. International Atlantic Economic Society, Peachtree Center 299, NEInternatio, Atlanta, 30303, Georgia, USA

    Katherine S. Virgo

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Humana Press

About this chapter

Cite this chapter

Mack, L.A., Bramwell, V.H.C. (2013). Soft Tissue Sarcoma Surveillance Counterpoint: Canada. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_45

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-969-7_45

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-968-0

  • Online ISBN: 978-1-60327-969-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation